Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00191230 · ClinicalTrials.gov registry record · Phase 2

Gemcitabine/Platinum Containing Regimens as Preoperative Chemotherapy for Patients With Non Small Cell Lung Cancer

A Phase 2 study of Carcinoma, Non-Small Cell Lung, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 2
Development phase
70
Enrollment target
1
Study location

NCT00191230: Completed Phase 2 study of Carcinoma, Non-Small Cell Lung, sponsored by Eli Lilly and Company.

NCT00191230 is a Phase 2 study of Carcinoma, Non-Small Cell Lung that has completed, run by Eli Lilly and Company. The registered enrollment target is 70 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00191230, a Phase 2 study of Carcinoma, Non-Small Cell Lung, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 2
Development phase
70 participants
Enrollment target
1
Study location

Study Summary

To study the efficacy and tolerability of gemcitabine/platinum chemotherapy in non small cell lung cancer

Conditions Studied

Carcinoma, Non-Small Cell Lung

Interventions

  • DRUG cisplatin
  • DRUG carboplatin
  • DRUG gemcitabine

Study Locations (1)

North Carolina

  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Chapel Hill

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2001-09
Est. Completion 2006-07
Phase Phase 2
Eli Lilly and Company

1,341 total trials

What the finished NCT00191230 record still lists

NCT00191230 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (78% lower).

The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 3 interventions - of which cisplatin is the first listed.

NCT00191230 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT00191230 about?

NCT00191230 is a clinical study titled "Gemcitabine/Platinum Containing Regimens as Preoperative Chemotherapy for Patients With Non Small Cell Lung Cancer". To study the efficacy and tolerability of gemcitabine/platinum chemotherapy in non small cell lung cancer

What is the current status of trial NCT00191230?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2001-09. Estimated completion is 2006-07.

What conditions does trial NCT00191230 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.

What interventions are being tested in trial NCT00191230?

The interventions under investigation include: cisplatin (DRUG), carboplatin (DRUG), gemcitabine (DRUG).

Who is sponsoring clinical trial NCT00191230?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00191230 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00191230's enrollment target sits among peer trials

70 83rd of 130 higher than 46 of 130 other Carcinoma, Non-Small Cell Lung trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00969111 · 70 participants · NA

    Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

  • NCT01712620 · 70 participants · Phase 2

    Spironolactone for Pulmonary Arterial Hypertension

  • NCT02143830 · 70 participants · Phase 2

    HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

  • NCT02601339 · 70 participants

    NIRS Monitoring in Premature Infants

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00191230, the US trial registry maintained by the National Library of Medicine. NCT00191230 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.